Quick Facts
Plain-English Summary
Note on blend construction: The BPC-157 + TB-500 dual blend is already catalogued separately in this library. The Regeno Blend adds GHK-Cu as a third component, extending the established pairing. The rationale for this addition — matrix repair and collagen induction — is theoretically complementary but has not been studied in combination with the other two peptides.
The Regeno Blend is a triple-component research formulation combining three peptides with overlapping but mechanistically distinct roles in tissue repair. It is the most popular blend in the biohacking community catalogue, building on the well-known BPC-157 + TB-500 pairing by incorporating GHK-Cu, a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine at concentrations that decline with age.
Each component carries its own independent preclinical evidence base. BPC-157 has the deepest research record, with 30+ years of rodent studies documenting angiogenic, gut-protective, and musculoskeletal repair effects. TB-500 — more precisely, the Tβ4 actin-binding fragment Ac-LKKTETQ — has demonstrated cell migration enhancement and muscle satellite cell activation in animal cardiac and musculoskeletal models. GHK-Cu has a substantial independent literature on collagen synthesis, wound healing, skin regeneration, and antioxidant signalling, studied independently of the other two components.
The appeal of combining all three is a proposed tissue repair cascade that maps onto three sequential stages: BPC-157 laying new vascular infrastructure at the injury site, TB-500 mobilising progenitor cells and driving their migration into the repair zone, and GHK-Cu stimulating the extracellular matrix reconstruction that consolidates the healed tissue. This narrative is mechanistically plausible — each step references real, independently supported biology.
The critical evidence gap is at the combination level. No peer-reviewed study has examined BPC-157 + TB-500 + GHK-Cu together in any model. The repair-cascade narrative is a theoretical synthesis of independent findings, not an experimentally demonstrated interaction. Synergistic, additive, or antagonistic effects between the three components are entirely unknown.
Human data remains nearly absent for all three components individually. BPC-157 has one incompletely published Phase II trial from the 1990s. TB-500 has no completed human clinical trials. GHK-Cu has the strongest translational data, with some human skin and wound-healing studies, but none in combination with BPC-157 or TB-500. The Regeno Blend as a formulation has no human trial data of any kind.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| BPC-157 — Tendon repair | Near-complete Achilles tendon healing at 4 weeks in rat transection model vs. untreated controls. Effect dose-dependent (1–10 μg/kg). Staresinic et al. 2003 ↗ | Preclinical |
| BPC-157 — Angiogenesis | Consistent VEGF upregulation and new capillary formation across muscle, tendon, and gastrointestinal tissue models. Proposed primary driver of cross-tissue healing effects. Sikiric et al. 2018 ↗ | Preclinical |
| TB-500 / Tβ4 — Cardiac repair | Thymosin Beta-4 promoted cardiomyocyte survival and vessel formation in rat myocardial infarction model. Active fragment Ac-LKKTETQ identified as key mediator of migration effect. Smart N et al. 2007 ↗ | Preclinical |
| TB-500 / Tβ4 — Muscle satellite cells | Tβ4 activated quiescent cardiac progenitor cells and promoted their migration. Demonstrated role in both embryonic development and adult tissue regeneration contexts. | Preclinical |
| GHK-Cu — Collagen synthesis | Copper tripeptide GHK-Cu stimulated collagen, elastin, and glycosaminoglycan synthesis in fibroblast and wound-healing models. Identified as naturally occurring wound-healing signal. Pickart L et al. 1988 ↗ | Preclinical |
| GHK-Cu — Wound healing | Accelerated full-thickness wound closure in multiple rodent and porcine models. Antioxidant copper chemistry proposed as secondary mechanism alongside matrix signalling. | Preclinical |
| Triple combination | No animal study has examined BPC-157 + TB-500 + GHK-Cu together in any model system. | No Data |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| BPC-157 | One Phase II trial in ulcerative colitis (62 patients, oral, 4 weeks, 1993) — not fully peer-reviewed. No other registered trials on ClinicalTrials.gov or EU CTR as of August 2026. | — | Incomplete |
| TB-500 / Tβ4 | No completed human clinical trials. Tβ4 has been studied as a topical wound treatment in small Phase I/II safety studies but not as the injectable fragment used in research blends. | — | No Data |
| GHK-Cu | Some human skin and wound-healing data from topical application studies. No injectable human trials. Provides the strongest individual translational signal in this blend. | — | Limited |
| Regeno Blend (triple) | No human trial data of any kind for this triple combination. No registered trial exists as of August 2026. | — | No Data |
Regeno Blend has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
No significant acute toxicity reported for BPC-157 or TB-500 in rodent studies at therapeutic doses. GHK-Cu has a strong individual safety record from topical and cosmetic applications. Combination safety has not been studied in any model.
BPC-157's VEGF upregulation and TB-500's cell migration effects could theoretically accelerate tumour vascularisation or proliferation in individuals with undetected malignancy. The angiogenic components compound each other's theoretical risk profile. No human data quantifies this.
- Injection site redness and mild soreness
- Transient headache in first days
- Mild nausea, particularly BPC-157 component
- Flushing or warmth (TB-500 community reports)
- No pharmacovigilance database exists for this blend
- Active or suspected malignancy
- Pregnancy or breastfeeding
- Immunosuppressive therapy
- Copper metabolism disorders (Wilson's disease)
- Children and adolescents
Regeno Blend is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Regeno Blend for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The GHK-Cu addition to the BPC + TB-500 base is the part I find most scientifically defensible — not because the triple combo is studied, but because GHK-Cu's mechanisms genuinely don't overlap with the other two in an obvious way. BPC drives vascular supply, TB-500 moves cells around, GHK-Cu lays down the collagen scaffold. If you're going to build a theoretical cascade, at least the components aren't redundant. Whether simultaneous dosing is smarter than sequential is a completely open question nobody has touched experimentally.
That's the point that gets hand-waved past constantly. GHK-Cu's clinical data is almost entirely topical — skin fibroblasts, wound beds, cosmetic applications. The injectable PK at 5mg systemic dose is essentially unknown. Whether the copper tripeptide reaches deep musculoskeletal tissue after subcutaneous injection, at a concentration that does anything useful, is not established.
What I think gets underappreciated is that BPC-157 and TB-500 are both angiogenic in their own right — BPC through VEGF, TB-500 through endothelial cell migration. So the vascular recruitment step isn't one mechanism, it's two overlapping ones. Adding GHK-Cu's copper-dependent lysyl oxidase activity on top of that means you've got three independently pro-regenerative signals running simultaneously. Whether that multiplies benefit or just creates a louder version of the same signal is genuinely unknowable from the current literature.
Honest take: the Regeno Blend is the BPC + TB-500 blend with a GHK-Cu upsell. The BPC + TB-500 combo is at least conceptually studied — there's community data on the pairing. The GHK-Cu addition is theoretically tacked on because it fits the narrative and GHK-Cu is generally regarded as safe and benign. That doesn't make it wrong, it just means the "triple synergy" framing is vendor storytelling more than evidence synthesis. Treat it as the dual blend with a matrix repair bonus that may or may not do anything at the injection dose.
This is the calibrated read. The cascade narrative is compelling enough that it gets taught as fact in biohacking circles. The honest version is: three peptides with independently reasonable mechanisms, no combination data, and a plausible but unverified story about how they might work together. High community enthusiasm does not substitute for the missing experiments.
For what it's worth: GHK-Cu has the clearest safety signal of the three, at least in topical use. The injectable version at 5mg is more speculative, but the copper tripeptide itself is endogenous — we all have plasma GHK-Cu, and it declines with age. That framing makes it an easier sell than the fully synthetic peptides. Whether that translates to subcutaneous injectable efficacy at this dose is the gap nobody can currently answer. The collagen induction data from fibroblast cultures is real; whether it's systemic at 5mg SC is not known.